News

Telitacicept (RC18), an experimental therapy being developed by RemeGen, significantly eased disease activity in people with primary Sjögren’s syndrome in a Phase 2 clinical trial, the company announced. “We are very excited to see the positive results from the Phase II clinical trial of telitacicept,” Jianmin Fang,…

Punctal plugs, which are inserted into the tear ducts to keep the eyes lubricated, are a mainstay of treatment for dry eye in people with primary Sjögren’s syndrome, a South Korean study found. The approach may be combined with additional treatments, but appropriate therapies will depend on the presence…

The experimental oral therapy cenerimod prevented immune cells from entering the salivary glands and reduced gland inflammation in two Sjögren’s syndrome mouse models, a study demonstrated. “These encouraging data suggest that cenerimod may be a promising approach to treating Sjögren’s syndrome,” the scientists said. The study, titled “…

A study has identified concerns common to people with primary Sjögren’s syndrome across five European countries, which researchers hope will help the development of more meaningful patient-reported outcomes and support medical professionals in providing better treatment options. The study, “The Experiences of Functioning and Health of Patients With…

Obstructive sleep apnea (OSA), which occurs when breathing slows or stops repeatedly for short times during sleep, is common among people with primary Sjögren’s syndrome, a study found. Since OSA is associated with an increased risk for cardiovascular problems, fatigue, and other medical problems, physicians should monitor all people with…

A clinical trial at the University of Texas Southwestern Medical Center in Dallas is currently recruiting people with autoimmune diseases, particularly Sjögren’s syndrome, who also have postural orthostatic tachycardia syndrome (POTS). The study, supported by a $150,000 joint grant from the Sjögren’s Foundation and Dysautonomia International, is…

Note: This story was updated Dec. 21, 2021, to note that Sjögren’s syndrome is not a rare disease, being estimated to affect 1-4 million people in the United States. While the vast majority of people with Sjögren’s syndrome are satisfied with their healthcare provider and medication, more than one…